22nd Century Group Inc. (XXII)

3.02
AMEX : Miscellaneous
Prev Close 3.02
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.88 / 4.44
Avg Volume 3.87M
Exchange AMEX
Shares Outstanding 123.56M
Market Cap 331.15M
EPS -0.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

First Week of March 16th Options Trading For 22nd Century Group (XXII)

Investors in 22nd Century Group Inc saw new options begin trading this week, for the March 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the XXII options chain for the new March 16th contracts and identified one put and one call contract of particular interest.

10 Favorite Healthcare Stocks for 2018: Medical Marijuana to Opioid Treatment

10 Favorite Healthcare Stocks for 2018: Medical Marijuana to Opioid Treatment

We see a notable shift away from traditional large-cap pharmaceutical stocks to more specialized niches.

First Week of February 2018 Options Trading For 22nd Century Group (XXII)

Investors in 22nd Century Group Inc saw new options become available this week, for the February 2018 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the XXII options chain for the new February 2018 contracts and identified the following call contract of particular interest.

22nd Century Hires Former BAT Head Of Plant Biotechnology

22nd Century Hires Former BAT Head Of Plant Biotechnology

22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company focused on tobacco harm reduction and hemp/cannabis research, announced today the hiring of Juan Sanchez Tamburrino, Ph.

22nd Century Ships 2.4 Million SPECTRUM® Cigarettes For The National Institute On Drug Abuse

22nd Century Ships 2.4 Million SPECTRUM® Cigarettes For The National Institute On Drug Abuse

22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company focused on tobacco harm reduction and hemp/cannabis research, announced today that the Company shipped 2.

Anticipating FDA's "Reduced Nicotine Mandate," 22nd Century Will Discontinue U.S. Sales Of RED SUN Brand

Anticipating FDA's "Reduced Nicotine Mandate," 22nd Century Will Discontinue U.S. Sales Of RED SUN Brand

22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company focused on tobacco harm reduction and hemp/cannabis research, announced today that, in preparation for the planned mandate by the U.

Interesting XXII Put And Call Options For July 2018

Interesting XXII Put And Call Options For July 2018

Investors in 22nd Century Group Inc saw new options begin trading this week, for the July 2018 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

22nd Century Group Files 2017 Third Quarter Report And Announces Conference Call To Provide Business Update

22nd Century Group Files 2017 Third Quarter Report And Announces Conference Call To Provide Business Update

22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is focused on tobacco harm reduction and hemp/cannabis research, announced today the Company's third quarter 2017 financial results and will...

22nd Century Hires Former Reynolds American Vice President

22nd Century Hires Former Reynolds American Vice President

22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company focused on tobacco harm reduction and cannabis/hemp research, announced today the hiring of James E.

First Week Of December 15th Options Trading For 22nd Century Group (XXII)

First Week Of December 15th Options Trading For 22nd Century Group (XXII)

Investors in 22nd Century Group Inc saw new options begin trading this week, for the December 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the XXII options chain for the new December 15th contracts and identified the following call contract of particular interest.

22nd Century Completes Successful Hemp Field Trials With University Of Virginia

22nd Century Completes Successful Hemp Field Trials With University Of Virginia

22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company focused on tobacco harm reduction and cannabis research, announced today that the Company and the University of Virginia ("UVA") completed their...

22nd Century Group Closes $54 Million Common Stock Only Registered Direct Offering

22nd Century Group Closes $54 Million Common Stock Only Registered Direct Offering

22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company focused on tobacco harm reduction, announced today that the Company has closed a registered direct common stock offering with institutional...

22nd Century Group Announces $54 Million Common Stock Only Registered Direct Offering

22nd Century Group Announces $54 Million Common Stock Only Registered Direct Offering

22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is focused on tobacco harm reduction, announced today that it has entered into an agreement with institutional investors to receive...

National Conference On "Tobacco Regulatory Science" To Address FDA's New Comprehensive Plan For Nicotine Regulation

National Conference On "Tobacco Regulatory Science" To Address FDA's New Comprehensive Plan For Nicotine Regulation

22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is focused on tobacco harm reduction, announced today that the Vermont Center on Behavior and Health's 5th Annual Conference will focus on...

22nd Century Now Free Of Restrictive License Agreement With British American Tobacco

22nd Century Now Free Of Restrictive License Agreement With British American Tobacco

22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is focused on tobacco harm reduction, is pleased to announce that the 2013 Research License and Commercial Option Agreement between the...

First Week of XXII November 17th Options Trading

Investors in 22nd Century Group Inc saw new options become available this week, for the November 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the XXII options chain for the new November 17th contracts and identified one put and one call contract of particular interest.

22nd Century To Speak At Global Tobacco & Nicotine Forum

22nd Century To Speak At Global Tobacco & Nicotine Forum

22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is focused on tobacco harm reduction, announced today that officials from the Global Tobacco & Nicotine Forum (GTNF) have invited the...

22nd Century Technology Is A "Game Changer"

22nd Century Technology Is A "Game Changer"

22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is focused on tobacco harm reduction, announced today that a growing number of independent scientists specializing in tobacco harm...

Interesting XXII Put And Call Options For April 2018

Interesting XXII Put And Call Options For April 2018

Investors in 22nd Century Group Inc saw new options become available this week, for the April 2018 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

22nd Century Group Files 2017 Second Quarter Report And Announces Conference Call To Provide Business Update

22nd Century Group Files 2017 Second Quarter Report And Announces Conference Call To Provide Business Update

22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is focused on tobacco harm reduction and cannabis research, announced today the Company's second quarter 2017 financial results and will...

FDA's Plan To Lower Nicotine In Cigarettes Has Captured The Attention Of Regulators And Public Health Experts Around The World

FDA's Plan To Lower Nicotine In Cigarettes Has Captured The Attention Of Regulators And Public Health Experts Around The World

22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is focused on tobacco harm reduction, announced today that, as reported in Bloomberg News, the landmark plan by the United States Food and...

Don't Buy Altria's Dip Following FDA Regulation Change, RBC Says

Don't Buy Altria's Dip Following FDA Regulation Change, RBC Says

This FDA regulatory change hasn't created a buying opportunity like past changes have.

FDA's Plan To Lower Nicotine In Cigarettes To Non-Addictive Levels Shines Spotlight On 22nd Century Group

FDA's Plan To Lower Nicotine In Cigarettes To Non-Addictive Levels Shines Spotlight On 22nd Century Group

22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is focused on tobacco harm reduction, stated today that the Company welcomes the announcement by the United States Food and Drug...

Tobacco Stocks Go Up in Smoke After FDA Issues Plan to Curb Tobacco-Related Deaths

Tobacco Stocks Go Up in Smoke After FDA Issues Plan to Curb Tobacco-Related Deaths

The FDA wants to protect children and limit tobacco-related diseases by changing the way cigarettes are made.

22nd Century Joins Russell Microcap® Index

22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced that, effective today, the Company joined the Russell Microcap ® Index, when FTSE Russell...

22nd Century Receives Guidance From FDA On Phase III Clinical Trials

22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced today that on June 20, 2017, the Company and its wholly owned subsidiary, Heracles...

22nd Century Partners With The University Of Virginia To Utilize Industrial Hemp To Clean Up And Reclaim Polluted Lands

22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company focused on tobacco harm reduction and cannabis research, announced today that, together with The University of Virginia (UVA), it has launched a...

TheStreet Quant Rating: D- (Sell)